National Priority Reviews (One-Month "National Interest" Reviews)

Summary

Commissioner Marty Makary’s March 2026 farewell statement on Dr. Vinay Prasad’s tenure credited him with launching “national priority reviews” — a policy under which certain drug applications serving “national interests” would receive one-month reviews, dramatically shorter than standard FDA timelines. The Associated Press reported the policy as part of a broader push to compress review timelines, alongside a mandate for expanded AI use by agency staffers.

Details of eligibility criteria and which applications qualified were thin in public reporting, and the policy was announced in the final weeks of Prasad’s second FDA stint. Supporters framed it as a overdue acceleration of access to important medicines; skeptics questioned whether speed could be sustained without sacrificing review quality.

Timeline

• March 2026 — Makary’s farewell statement credits Prasad with launching “national priority reviews”; AP reports the policy as one-month reviews for drugs serving “national interests.”
• April 30, 2026 — Prasad departs the FDA; implementation of the accelerated review track continues under agency leadership.